Bio-Rad Laboratories, Inc. (BIO.B) income statement

BIO.BNYSELaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BIO

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 8/3055% above fair value

$379.50+0.00 (0.00%)

Close on Oct 29, 2026Market cap $10.18BP/E 46.2Yield –

Bio-Rad Laboratories, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31	TTM Q3 2021 2021-09-30	TTM Q2 2021 2021-06-30	TTM Q1 2021 2021-03-31	TTM FY 2020 2020-12-31	TTM Q3 2020 2020-09-30	TTM Q2 2020 2020-06-30	TTM Q1 2020 2020-03-31	TTM FY 2019 2019-12-31	TTM Q3 2019 2019-09-30	TTM Q2 2019 2019-06-30	TTM Q1 2019 2019-03-31	TTM FY 2018 2018-12-31	TTM Q3 2018 2018-09-30	TTM Q2 2018 2018-06-30	TTM Q1 2018 2018-03-31	TTM FY 2017 2017-12-31	TTM Q3 2017 2017-09-30	TTM Q2 2017 2017-06-30	TTM Q1 2017 2017-03-31	TTM FY 2016 2016-12-31	TTM Q3 2016 2016-09-30
Revenue	2,589	2,590	2,583	2,558	2,554	2,541	2,567	2,580	2,563	2,605	2,671	2,720	2,769	2,779	2,802	2,805	2,871	2,896	2,923	2,980	2,880	2,701	2,546	2,380	2,294	2,329	2,312	2,304	2,289	2,292	2,289	2,294	2,283	2,212	2,160	2,110	2,085	2,097	2,068	2,067
Cost of Revenue	1,246	1,247	1,243	1,221	1,205	1,182	1,188	1,177	1,180	1,215	1,244	1,263	1,274	1,252	1,235	1,236	1,237	1,256	1,284	1,280	1,250	1,180	1,108	1,072	1,046	1,067	1,055	1,045	1,050	1,059	1,066	1,058	1,035	992	972	954	948	953	930	935
Gross Profit	1,344	1,343	1,340	1,337	1,349	1,359	1,379	1,403	1,383	1,390	1,427	1,458	1,495	1,527	1,567	1,570	1,634	1,640	1,638	1,698	1,629	1,521	1,438	1,308	1,248	1,263	1,257	1,259	1,239	1,233	1,223	1,236	1,248	1,220	1,188	1,157	1,137	1,144	1,138	1,132
Research & Development	266	265	276	285	305	303	296	280	233	239	247	250	273	272	257	250	247	246	261	259	254	242	218	218	206	204	203	199	200	197	199	222	235	250	250	232	220	207	206	204
Selling, General & Admin	852	848	844	827	821	808	814	817	818	831	842	847	857	857	828	837	842	848	877	873	855	831	799	795	799	811	825	824	824	833	835	823	820	822	807	825	828	821	815	790
Operating Income	53	58	47	224	224	248	269	306	332	320	338	361	365	398	483	482	544	546	500	568	521	448	421	295	243	247	230	-57	-78	-90	-103	170	172	127	119	35	19	48	56	129
Interest Expense	49	49	49	49	49	49	49	49	49	49	49	49	48	46	38	27	16	5.20	1.55	5.89	11	17	22	23	23	23	23	23	24	24	24	24	23	23	23	24	24	23	23	23
Interest & Investment Income	88	80	96	81	82	84	82	83	85	85	101	97	87	76	58	46	38	33	19	23	24	34	18	18	20	14	31	33	32	44	27	26	24	20	19	16	16	15	15	15
Other Non-Operating Income	85	77	90	81	91	93	90	90	92	91	107	90	72	63	45	52	49	42	27	20	21	39	24	21	24	11	26	34	32	44	37	27	25	21	11	13	14	14	14	16
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	13	–
Asset Impairment Charges	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	293	–	–	–	12	–	–	–	62	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	–	–	–	-2.50	–	–	–	-1.40	–	–	–	0	-24	-24	-12	-12	12	12	0.20	0	-0.30	-0.30	-0.30	4.10	4.10	4.10	4.10	0	0.17	–	–	0	–
Pretax Income	350	222	996	-843	450	-2,750	-2,343	-1,005	-1,730	-444	-850	-187	-532	-251	-4,704	-7,823	-2,593	-216	5,449	8,565	5,227	5,317	4,918	4,529	2,509	2,033	2,261	520	1,206	776	513	1,600	1,280	941	98	24	16	42	42	124
Income Tax Expense	128	54	236	-167	131	-586	-498	-227	-404	-121	-213	-28	-103	-60	-1,077	-1,802	-663	-126	1,195	1,898	1,174	1,211	1,104	1,008	562	453	502	144	301	202	147	323	251	175	-24	2.84	-0.08	14	16	34
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	98
Net Income	222	169	760	-676	319	-2,164	-1,844	-779	-1,326	-322	-637	-159	-428	-191	-3,628	-6,027	-1,935	-93	4,254	6,666	4,051	4,100	3,814	3,521	1,947	1,579	1,759	377	905	574	366	1,277	1,030	767	122	21	16	27	26	94
EPS (Basic)(per share)	8.33	6.11	27.87	-24.31	11.76	-76.17	-65.36	-27.28	-47.00	-10.33	-21.82	-5.72	-14.85	-6.31	-121.79	-201.57	-64.29	-2.44	142.61	223.59	136.03	137.82	128.13	118.30	65.38	52.87	58.93	12.70	30.40	19.31	12.25	42.84	34.56	25.74	4.12	0.70	0.54	0.93	0.88	3.21
EPS (Diluted)(per share)	8.25	6.07	27.85	-24.31	11.73	-76.20	-65.36	-27.33	-47.03	-10.36	-21.82	-5.85	-14.97	-6.43	-121.79	-201.57	-66.07	-4.61	140.83	220.70	134.32	136.06	126.47	116.82	64.50	52.21	58.27	12.19	29.76	18.77	12.10	42.28	34.12	25.42	4.07	0.68	0.53	0.92	0.88	3.19
Shares Outstanding (Basic, Weighted)(shares)	27	27	27	28	28	28	28	28	29	29	29	29	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	29	29	29
Shares Outstanding (Diluted, Weighted)(shares)	27	27	27	28	28	28	28	28	29	29	29	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30	30
EBITDA	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	382	364	78	58	46	35	316	319	276	268	174	161	190	199	273

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 51.9%
Operating margin: 2.1%
Net margin: 8.6%
Return on equity, FY2025: 10.8%

Financial strength

Current ratio: 3.14
Debt to equity: 0.11
Debt to assets: 7.8%
Cash to current liabilities: 53.8%

Valuation

P/E ratio: 46.2
Price to sales: 3.93
Price to book: 1.42
Dividend yield: –